Zelluna Immunotherapy, an Oslo, Norway-based T Cell Receptor (TCR) cell therapy company, raised €7.5m in equity funding and public grants.
The company intends to use the funds for the development of its proprietary TCR guided Natural Killer (NK) cell therapy platform (TCR-NK) and novel TCR-NK products for the treatment of cancers.
Led by Namir Hassan, CEO, Zelluna Immunotherapy is a company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company will secure new TCR targets through both internal development programs and in partnerships with other companies and groups. In support of this strategy, Zelluna has recently announced the formation of partnerships with NK organizations, providing access to NK cells, manufacturing facilities and additional competency and expertise.